Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21760602.
- Also identified by DOI 10.1038/ki.2011.133.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Erythropoiesis-stimulating agents (ESAs) have been used for about three decades in chronic kidney disease patients to treat the symptoms of anemia, avoid potentially hazardous blood-product transfusions, improve some facets of quality of life, and reduce cardiovascular risk. We review a new article in which this association between stroke and ESA use is examined in a different population in a different way, but with the same worrying findings as seen in the TREAT study.
Medical subject headings
- Anemia
- Hematinics
- Kidney Diseases
- Stroke